South San Francisco, February 25 2019
Hummingbird Bioscience announced today it has been awarded a product development grant totalling $13.1 million by the Cancer Prevention and Research Institute of Texas (CPRIT).
The grant will support the Phase IA/B clinical trials of the
company's first-in-class anti-VISTA therapeutic antibody for the treatment of
VISTA mediated suppression of anti-tumor immunity in solid tumors and lymphomas
that are unresponsive to existing therapies. Hummingbird Bioscience is a
systems-biology enabled biotech company focused on the discovery and
development of novel cancer therapeutics.
The CPRIT review for this grant included an in-depth evaluation
of HMBD-002, an antibody that uniquely neutralizes VISTA function, by a panel of
scientific, medical, and industry experts. The evaluation included rigorous
review of the pre-clinical data, as well as regulatory, research and
development, and intellectual property due diligence.
The grant will support the Phase IA/B clinical study and preparatory steps
including GMP manufacturing and Investigational New Drug (IND) submission for
the HMBD-002 program. The grant will also support the relocation of the
company's U.S. headquarters to Texas.
Clinical trials for HMBD-002 are anticipated to begin in 2020. Hummingbird Bioscience
was the only successful application of its type for this grant cycle.
The award follows the recent announcement of Nobel Laureate James P. Allison,
Ph.D. and Padmanee Sharma, M.D., Ph.D. joining
Hummingbird's Scientific Advisory Board.
"We are delighted to be awarded this highly-selective grant from
CPRIT and to start building our operations in Texas,"
said Piers Ingram, Ph.D., CEO of Hummingbird Bioscience.
"Our company applies systems biology approaches to generate uniquely
differentiated therapeutic antibodies. We are thrilled CPRIT's panel of
experts agrees that developing this anti-VISTA immuno-oncology program has the
potential to significantly benefit patients."
Hummingbird Bioscience is an innovative therapeutics development
company with a proprietary rational antibody discovery platform and deep
experience in applying integrative genomics and proteomics. Hummingbird
develops precision therapeutic antibodies to clinical proof-of-concept for
patients with the highest unmet need. The company has a pipeline of first or
best-in-class drug candidates. Within its pipeline, HMBD-001 (anti-HER3
antibody) and HMBD-002 (anti-VISTA antibody) are anticipated to start clinical
trials in 2020. The company has locations in South San Francisco, CA and
Singapore. For more information on Hummingbird Bioscience visit: http://www.hummingbirdbioscience.com
McDougall Communications on behalf of Hummingbird Bioscience
Contact: Elizabeth Harness, firstname.lastname@example.org, Tel: +1 (585) 435 -7379